Malaysia dengue cases surge as vaccine uptake remains low
Dengue infections in Malaysia rose 56.2 per cent in 2026, with 58,079 cases and 55 deaths recorded so far, while vaccine take-up remains low due to cost and limited awareness. Stakeholders said two-dose regimens cost about RM420–RM500, with private facilities charging up to RM480, and the vaccine is recommended for people aged four to 60 but is not suitable for pregnant, breastfeeding or immunocompromised patients. The Health Ministry reported concentrated rises in the Klang Valley and noted increases in several states, and it has begun intensive prevention, vector control and outbreak management measures to curb transmission.
Dengue cases rose 56.2 per cent while vaccine uptake remains low.
Context
Dengue cases rose sharply, first concentrated in the Klang Valley. The Health Ministry started intensive prevention and control measures. Cases could spread more widely if uptake stays low.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked